Associate Professor Tarek Meniawy is a medical oncologist who subspecialises in melanoma, gynaecological cancers as well as early-phase clinical trials. He is an Adjunct Associate Professor at Edith Cowan University and a Clinical Senior Lecturer at the University of Western Australia, where has was awarded a PhD degree in 2016. He is an active clinical and translational researcher, and is involved in early drug development as a Principal Investigator at Linear Clinical Research, the only dedicated Phase I unit in Western Australia, and one of a handful of such dedicated units in Australia. A/Prof Meniawy is Chair of the ANZGOG Ovarian Tumour Working Group and serves on the Research Advisory Committee and OASIS Steering Committee. He is also a member of the statewide Western Australia Gynaecologic Cancer Service (WAGCS), as well as the WA Kirkbride Melanoma Advisory Service.

Professor Clare Scott is a Medical Oncologist at the Royal Melbourne Hospital and Royal Women’s Hospital and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research, studying drug resistance in ovarian cancer. She has 15 years’ experience in clinical cancer genetics, including working in Familial Cancer Clinics and in treating breast and ovarian cancer. In the lab, she focuses on ovarian biology, including the role of apoptosis in infertility and on developing targeted therapies for ovarian cancer in novel ovarian cancer models. She has been awarded a Clinical Fellowship from the Victorian Cancer Agency (2011) and the Sir Edward Dunlop Cancer Research Fellowship from the Cancer Council Victoria (2012). Professor Scott is a very active member of ANZGOG, she is an ANZGOG Director, the current Chair of the ANZGOG OASIS Committee and sits on the ANZGOG Research Advisory Committee, the Ovarian Tumour Type Working Group and the TR-ANZGOG Steering Committee.

Associate Professor Lyndal Anderson is a medical graduate of the University of Tasmania and commenced Pathology training in England in 2000. In Australia she trained at St Vincent’s Hospital Sydney and the Royal Prince Alfred Hospital before completing her Fellowship from the Royal College of Pathologists of Australasia in 2005.  She completed a Master of Philosophy in Gynaecological Pathology with The University of Sydney in 2011 and a Masters of Health Management with The University of New South Wales in 2012.  Her primary interests include Gynaecological Pathology and Cytopathology.  She is a Senior Staff Specialist at Royal Prince Alfred Hospital, an Associate Professor at Western Sydney University and an Associate Professor at The University of Sydney.  She is a member of the Research Advisory Committee for ANZGOG and a member of the Translational Research at ANZGOG committee.  She is the current President of the Australian Society of Cytology.

Professor Nicklin is a graduate of the University of Queensland.  He did his internship and residency at the Royal Brisbane and Royal Women’s Hospitals.  He subsequently went on to do specialty training in obstetrics and gynaecology in Queensland.  He then did his sub-specialty training in gynaecologic oncology at the Royal Hospital for Women in Sydney and the Ohio State University, USA.  He returned to Queensland and set up practice as a gynaecologic oncologist in late 1995.  He is currently a Professor of Gynaecologic Oncology at University of Qld, Director of Gynaecologic Oncology at RBWH, a past Chairman of Australian Society of Gynaecologic Oncologists (ASGO), a member of ANZGOG, a member of the CGO subspecialty committee of RANZCOG and conducts his private practice at the Wesley Hospital, Brisbane.  He has a particular interest in medical aid work.  He goes to Fiji annually for medical aid work and teaching, and is an International Gynecologic Cancer Society mentor to the area.

Professor David Bowtell is co-Head of the Women’s Cancer Program at the Peter MacCallum Cancer Centre and a Fellow of the Australian Academy of Science. He was Director of Research at Peter Mac for a decade from 2000-2009, during which time he co-led planning and the case to government funding of the new Peter Mac in Parkville. Professor Bowtell has an extensive background in human cancer genome sequencing, with a focus on acquired drug resistance, exceptional survival, and clinical trials in ovarian cancer. He is Head of the Australian Ovarian Cancer Study (AOCS), one of the largest studies of ovarian cancer in the world.  Professor Bowtell is a long standing member of the ANZGOG Research Advisory Committee, the OASIS Steering Committee and the Ovarian Tumour Working Group.

Dr Yeh Chen Lee is a medical oncologist with subspecialty expertise in gynaecological cancers. She is currently a Staff Specialist at the Prince of Wales – Royal Hospital for Women and Royal Prince Alfred-Chris O’Brien Lifehouse; and a Research Fellow at the NHMRC Clinical Trials Centre, University of Sydney and Conjoint Senior Lecturer at the University of New South Wales.  Dr Lee’s research focus is to improve patient care in gynaecological cancers, through advancing and translating knowledge in cancer genetics, drug development and supportive care. She completed a dual research fellowship at Peter MacCallum Cancer Centre (Melbourne, Australia; 2015-2016) and at Princess Margaret Cancer Centre (Toronto, Canada; 2016-2018) in Gynaecology and Drug Development. She was awarded Master of Philosophy with first class honours (University of Melbourne) investigating ways to improve ovarian cancer care along the disease trajectory. Dr Lee is highly active in clinical trials in gynaecological cancers and has been involved in the conduct of >30 Phase I-III investigator-initiated and collaborative trials. Dr Lee is a member of the ANZGOG Research Advisory Committee and sits on the Ovarian Tumor Working Group and is involved with the ANZGOG ASM 2022 Program Steering Committee.

Dr Kate Webber is a medical oncologist at Monash Health and adjunct senior lecturer at Monash University. She has a keen interest in breast and gynaecological oncology, cancer survivorship and patient reported outcomes research.  Kate’s PhD and subsequent research has encompassed studies exploring the prevalence, predictors and trajectories of physical and psychological symptoms after cancer treatment, lifestyle and behavioural interventions, and novel models of delivery of survivorship care. She is a member of the COSA Survivorship and Patient Reported Outcomes Working Groups and her research team at Monash Health is currently exploring implementation of real time patient reported outcome measures into routine cancer care. Kate is the current co-chair of the Cancer Institute NSW eviQ Medical Oncology Reference Committee and will be convening the Clinical Oncology Society of Australia ASM in 2021.

A/Prof Kathy Tucker is one of the leading cancer geneticists in Australia. She founded the first Australian Familial Cancer Service in 1994 and is the former head of Hereditary Cancer Centre, Prince of Wales Hospital and a conjoint at the University of New South Wales POWH Clinical school. Since founding this service, A/Prof Tucker has been actively involved in local, state-wide and national working parties on genetics service and policy development. She led the development of telehealth as an additional medium to care for cancer genetic patients and their families. She is a key contributor to the cancer genetics stream of the NSW Cancer Institute- Evidence into Clinical Practice – eviQ.org.au.

She is the clinical geneticist on multiple national Zero Childhood Cancer Projects and the MoST and RISC study at Genomic Cancer Medicine at the Garvan where she leads the ethical return of germline cancer predisposition results. She has long been a strong advocate of ensuring ethical practice in genetics and positive psychosocial outcomes, generating research and education initiatives on these issues. A/Prof Tucker was awarded an Officer of the Order of Australia in June 2018’s AO for her distinguished service to medicine in the field of familial cancer genetics. She was also recognized for her work as a clinician, researcher and author; and for her contribution to medical education and to professional bodies.

Dr Helen Gooden is National Manager of the ANZGOG ‘Survivors Teaching Students®’ program. Helen is an experienced nurse, researcher and health consultant with project and grant management experience across the health sector in the tertiary, government and not-for-profit sector with specialist experience in ovarian cancer.

Her doctoral research focussed on psychosocial support for people affected by pancreatic cancer and her ongoing research interest is in translational research improving patient outcomes in cancer, health communication and involving consumers in research.

Wanda Lawson is the Consumer Director on the ANZGOG Board of Directors and the Chair of the Consumer Research Panel since 2018.  She is a retired Business and Change Management Consultant, previously running her own company in the delivery of business solutions. She joined the ANZGOG Consumer Community Committee in 2011 after several years as a member of Cancer Voices QLD. She was appointed to the Research Advisory Committee in 2012 and is also involved with the Tumour Type Working Groups, the EDEN initiative and the ANZGOG Annual Scientific Meeting steering committee. Wanda is also an Associate Investigator on several gynaecological trials.

In 2004 she was diagnosed with ovarian cancer. Since then, she has focused her skills on campaigning for better outcomes for women diagnosed with gynaecological cancers.

Jane Power’s consumer experience commenced in 2014; She is currently the chairperson for Mercy Women’s Hospital CAG, also a committee member for the Cancer Support Care and Choosing Wisely committees and conducts reviews for sentinel events. In 2017, she was appointed Melbourne Coordinator for the ‘Survivors Teaching Students’ program and in 2019 became a member of the ANZGOG Consumer Research Panel. Jane also sits on the ANZGOG Ovarian Tumour Working Group and is a committee member for a National Ovarian Cancer Clinical Trial.

Jane is an active member of the Friends of the Bowtell Research Laboratory.  In addition she has provided consumer input at Safer Care Victoria.

As an ovarian cancer survivor she is committed to make a difference, contributing to improving outcomes for women from all walks of like experiencing a gynaecological cancer diagnosis, who all need the best treatment options and standard of care Australia has available.